Board of Directors
Nationality: Switzerland
Year of birth: 1964
Position: Chairman of the Board of Directors
Member1,2 since: 2020
Gilbert Achermann, member of the Board of Directors of Ypsomed Holding AG.
After completing his banking apprenticeship at the Bankverein and HWV in St. Gallen, he worked from 1988 to 1998, at UBS in investment banking in Switzerland and abroad.
In 1998 he moved to the MedTech industry as CFO at Straumann, where he was appointed CEO in 2002 and Chairman of the Board of Directors of Straumann Holding AG in 2010. In this function, he has been a member of the Board of Directors of the academic partner organisation ITI (International Team for Team for Implantology).
In addition, Gilbert Achermann was Chairman of the Board of Directors of Siegfried Holding AG in Zofingen (2011 to 2014) and of Vitra Holding AG in Birsfelden (2012 to 2015).
Since 2012 he has been a member of the Board of Directors of the private bank Julius Baer, since 2016 a member of the Chamber of Commerce of both Basel cantons and a member of the Supervisory Board of IMD – International Institute for Management Development in Lausanne, since 2020 a member of the Board of Directors of Swiss Medtech as well as since 2022 a member of the Board of Directors of greenTEG AG in Rümlang and a member of the Board of Directors of Unilabs in Kopenhagen, Denmark.
He is also involved in Venture Kick as a juror and is an active inves tor in Swiss start-ups.
Nationality: Swiss and Turkish
Year of birth: 1976
Position: Member of the Board of Directors
Member1 since: 2021
Betül Susamis Unaran, member of the Board of Directors of Ypsomed Holding AG.
After graduating from Bogazici University with a degree in industrial engineering, she started her career working in several positions at Procter & Gamble in Istanbul and Frankfurt. Following her MBA at INSEAD, she joined McKinsey & Company as a consultant in 2004 and worked in London and Geneva offices in different industries with a focus on healthcare, strategy and transformation. From 2012-2017 she worked at Ferring Pharmaceuticals where she acted first as Director of Global Operations and then as Global Head of Digital. From 2018 to 2019, she was Global Head of Digital Medicines at Novartis Pharmaceuticals and a member of the Novartis Pharma Global Commercial Leadership Team and the Novartis Global Digital Leadership Team.
From 2019 to 2022, she worked as Chief Strategy and Digital Officer at the Zur Rose Group AG, the largest e-commerce pharmacy in Europe. Since April 2023 she works as Chief Commercial Officer at Unilabs. Betül Susamis Unaran was a member of the Advisory Board of NATIVE in 2020, a leading design agency in London and San Francisco. Since 2022, she has been a member of the Board of Directors of DSS Sustainable Solutions Holding SA, Versoix in the Canton of Geneva, and of Brain+ A/S, which is listed in Denmark. She is also a member of the Advisory Board of Lumanity, an Arsenal Capital Partners company, with the vision to accelerate and optimise access to advances in medicine.
Nationality: US and Belgium
Year of birth: 1961
Position: Member of the Board of Directors
Member1,2 since: 2018
Paul Fonteyne, member of the Board of Directors of Ypsomed Holding AG.
After graduating from Brussels University with a degree in chemical engineering and an MBA from Carnegie Mellon University in Pittsburgh, he held various positions at Abbott Laboratories Inc. and Merck and Co. Inc.
He joined the Boehringer Ingelheim Group in 2003. For the first five years, he headed the Human Pharmaceuticals Division in the USA. From 2008 to 2011, he lived in Germany to lead the worldwide marketing team for human pharmaceuticals.
From 2012 to 2018, he was Chairman of the Board of Directors and CEO of Boehringer Ingelheim USA as well as Country Managing Director for the United States. Paul Fonteyne previously served as Chairman of the National Pharmaceutical Council (NPC), and was a member of the board of Pharmaceutical Research and Manufacturers of America (PhRMA), as well as ResTORbio Inc. (until 2020) and AMAG Pharmaceuticals Inc. (until 2020) and of Covetrus Inc. (until 2022).
He is currently a member of the Board of Directors of the four biotechnology companies Amylyx Pharmaceuticals Inc., Gelesis Inc. and Appelis Pharmaceutical Inc., all based in Boston, and DalCor Inc., based in London.
He is associated as Executive in Residence with Canaan Partners (Venture Capital).
Nationality: Germany and Switzerland
Year of birth: 1970
Position: Member of the Board of Directors
Member1 since: 2019
Dr. Martin Münchbach, member of the Board of Directors of Ypsomed Holding AG.
After graduating from the ETH Zurich in natural sciences with a doctorate in protein chemistry and a post-graduate degree in economics, business and management sciences from the ETH Zurich, he worked in various positions for venture capital companies in Switzerland.
He is currently Managing Partner of Pureos Bioventures, a venture capital company specializing in early-stage financing for the promotion of innovative young drug development companies with a focus on Switzerland and Europe. Through his work as a venture capitalist, he has built up numerous medical technology and biotechnology companies that have brought innovative drugs and diagnostics to market.
Martin Münchbach was a member of the Board of Directors of Binx Health Ltd. in Trowbridge, UK, until November 2022 and is presently a member of the Board of Directors of Ariceum Therapeutics in Berlin, Germany, Alentis Therapeuthics AG in Basel and River Renal Inc. in New York USA.
Nationality: Switzerland
Year of birth: 1977
Position: Member of the Board of Directors
Member2,3 since: 2022
Simon Michel, member of the Board of Directors of Ypsomed Holding AG.
CEO of the Ypsomed Holding AG
With Ypsomed since October 2006.
Member of Executive Management since 2008 and responsible for Marketing & Sales
CEO since July 2014.
From 2003 until 2006, Simon Michel worked for Orange Communications AG.
Simon Michel studied economics at the University of St. Gallen and completed a Masters with a focus on media and communications management.
He is a Member of the Board of Directors of Unitectra AG, sitem-insel AG, Forster Rohner AG and of LEM Surgical AG. Simon Michel has been a member of the board of the Chamber of Commerce in the Cantons of Berne and Solothurn and since 2015 a member of the board of Swiss Medtech since 2015.
Since 2017, he has been Chairman of the Board of Directors of DCB Research AG, which works closely with the University Hospital UDEM of the Insel Group in Switzerland and researches new therapeutic approaches to improve the quality of life of people with diabetes. Since 2021, he has also been Chairman of the Board of Ahueni AG, which is involved in the development and trading of CO2 certificates in Africa.
Simon Michel was elected to the Cantonal Council of the Canton of Solothurn in March 2017.
1 Non-executive member of the Board of Directors: no operational activity for Ypsomed Holding AG and its subsidiaries in the current year and the three preceding financial years.
2 Member of the Nomination & Compensation Committee.
3 Executive member of the Board of Directors.
Executive Board
Nationality: Switzerland
Year of birth: 1977
Position: CEO of the Ypsomed Holding AG
At Ypsomed since: 2006
With Ypsomed since October 2006.
Member of Executive Board since 2008 and responsible for Marketing & Sales.
CEO since July 2014.
From 2003 until 2006, Simon Michel worked for Orange Communications AG.
Simon Michel studied economics at the University of St. Gallen and completed a Masters with a focus on media and communications management.
He is a Member of the Board of Directors of Unitectra AG, sitem-insel AG, Forster Rohner AG and LEM Surgical AG. Simon Michel has been a member of the board of the Chamber of Commerce in the Cantons of Berne and Solothurn and since 2015 a member of the board of Swiss Medtech since 2015.
Since 2017, he has been Chairman of the Board of Directors of DCB Research AG, which works closely with the University Hospital UDEM of the Insel Group in Switzerland and researches new therapeutic approaches to improve the quality of life of people with diabetes. Since 2021, he has also been Chairman of the Board of Ahueni AG, which is involved in the development and trading of CO2 certificates in Africa.
Simon Michel was elected to the Cantonal Council of the Canton of Solothurn in March 2017.
Nationality: Germany and Switzerland
Year of birth: 1969
Position: Chief Business Officer (CBO) YDS
At Ypsomed since: 2001
With Ypsomed (pre-2003 with Disetronic) since 2001 in different functions. Since 2014 she is a member of Executive Board and responsible for the Delivery Systems business area. Previously she was Product Manager with Mettler Toledo (1996 – 2001).
She has a degree in chemical engineering and biotechnology at the University of Applied Sciences Aachen and completed a postgraduate diploma in International Management at the Kalaidos University of Applied Sciences in Zurich.
Nationality: Swiss
Year of birth: 1970
Position: Chief Business Officer (CBO) YDC
At Ypsomed since: 29 June 2022
Sébastien Delavire is at Ypsomed since 2022. From 2000 until 2022, he held various management positions in France, Scandinavia, the USA, Japan as well as Latin America with the pharmaceutical company Sanofi and was most recently responsible for the Medicine Division as Head of Europe. After completing his studies, he started his career in sales at Astra Pharmaceutica AG, Dietikon, and Biokema SA, Crissier. Sébastien Delarive studied chemistry at the ETH Lausanne (EPFL).
Nationality: Switzerland
Year of birth: 1963
Position: Chief Financial Officer (CFO)
At Ypsomed since: 2002
With Ypsomed (pre-2003 with Disetronic) since 2002, prior to that Head of Finance and Controlling for the industrial services product line of the Von Roll Group (from 1995 until 2002) and various advisory and accounting functions within a trust and auditing company. Education: Swiss certified expert in accounting and controlling.
Nationality: Germany and Switzerland
Year of birth: 1964
Position: Chief Operating Officer (COO)
At Ypsomed since: 2015
With Ypsomed since 2015 as a Member of Executive Board and responsible for Production, Supply Chain and QM&RA.
He has many years of experience in the development and manufacturing of medical devices: former COO and member of management at Nobel Biocare AG, responsible for the global production sites and global supply chain. In the years 2001 to 2012 he held various management functions in the Straumann Group in Switzerland and the USA in the areas of quality management, production and development.
After graduating, he started his career at Hoffmann La Roche AG in Basle in the Engineering Department (1990 – 1999). Of German-Swiss dual nationality, he graduated as Dipl. Ing. Mechanical Engineering from the Technical University Karlsruhe followed by further training at the IMD Lausanne and the Harvard Business School (AMP Programme).
From 2017 to 2021 he was a member of the Board of Directors at Qualitech AG. He has also been a member of the Board of Directors at Nemis Technologies AG since 2021.
Nationality: Switzerland
Year of birth: 1972
Position: Chief Corporate Officer (CCO)
At Ypsomed since: 2017
With Ypsomed since 2017. Since 2020 Chairman of the Board of Trustees of the Ypsomed Group Pension Fund Foundation. From 2011 to 2017 he was employed as Head of Talent Europe at ABB. Previous positions included HR at Credit Suisse: Division HR Manager, Head of Graduate Recruiting & Development and University Marketing (1997 to 2004). Furthermore he was Consultant and Management Member at schärpartners ag (2004 to 2007), Head of HR Services at Valiant Holding (2007 to 2008) and Head of HR Recruiting at BKW FMB AG (2008 to 2011).
Michael Zaugg held several part-time mandates: Member of the Board of Directors at Poolside AG in Zurich, Member of the Board at IngCH, lecturer at the ZfU and the University of St. Gallen Further Education Centre in the field of Talent Management, as well as the Bern University of applied sciences on the topic of “Leadership in an innovative environment”, and President of the ABB Childcare Centres.
Education: Study of Economics at the University of Basel (degree: lic.rer. pol) with business focus on personnel management, marketing and environmental economics; completion of interfaculty concomitant university studies in Mankind – Society – Environment (MGU); Executive Master of Human Resources Management at the Institute of Applied Psychology in Zurich.
Nationality: Switzerland
Year of birth: 1971
Position: Chief Legal Officer (CLO)
At Ypsomed since: 2023
Dr. Nicolas Meyer acted as General Counsel at the EMS Group for eight years and has spent the past three years as General Counsel and General Secretary at RUAG, where he accompanied the division of the Group. Prior to that, he worked for around ten years as an attorney at law at Lenz Caemmerer in Basel. Nicolas Meyer received his PhD in intellectual property law in 2004 and his Master of Law degree from the University of Basel in 1997.
